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Purpose: Novel strategies are being applied for creating better in vitro models that simulate in vivo conditions for testing
the efficacy of anticancer drugs. In the present study we developed surface-engineered, large and porous, biodegradable,
polymeric microparticles as a scaffold for three dimensional (3-D) growth of a Y79 retinoblastoma (RB) cell line. We
evaluated the effect of three anticancer drugs in naïve and nanoparticle-loaded forms on a 3-D versus a two-dimensional
(2-D) model. We also studied the influence of microparticles on extracellular matrix (ECM) synthesis and whole genome
miRNA-gene expression profiling to identify 3D-responsive genes that are implicated in oncogenesis in RB cells.
Methods: Poly(D,L)-lactide-co-glycolide (PLGA) microparticles were prepared by the solvent evaporation method. RB
cell line Y79 was grown alone or with PLGA–gelatin microparticles. Antiproliferative activity, drug diffusion, and cellular
uptake were studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole (MTT) assay,
fluorescent microscope, and flow cytometry. Extra cellular matrix (ECM) synthesis was observed by collagenase assay
and whole genome miRNA-microarray profiling by using an Agilent chip.
Results: With optimized composition of microparticles and cell culture conditions, an eightfold increase from the seeding
density was achieved in 5 days of culture. The antiproliferative effect of the drugs in the 3-D model was significantly
lower than in the 2-D suspension, which was evident from the 4.5 to 21.8 fold differences in their IC50 values. Using
doxorubicin, the flow cytometry data demonstrated a 4.4 fold lower drug accumulation in the cells grown in the 3-D model
at 4 h. The collagen content of the cells grown in the 3-D model was 2.3 fold greater than that of the cells grown in the 2-
D model, suggesting greater synthesis of the extracellular matrix in the 3-D model as the extracellular matrix acted as a
barrier to drug diffusion. The microarray and miRNA analysis showed changes in several genes and miRNA expression
in cells grown in the 3-D model, which could also influence the environment and drug effects.
Conclusions: Our 3-D retinoblastoma model could be used in developing effective drugs based on a better understanding
of the role of chemical, biologic, and physical parameters in the process of drug diffusion through the tumor mass, drug
retention, and therapeutic outcome.
A  suitable  three  dimensional  (3-D)  culture  system
provides  a  more  physiologically  relevant  approach  to  the
analysis of gene function, regulation, and cell phenotype ex
vivo [1]. It has previously been shown that engineering the
cell culture micro-environment to create growth conditions
that more accurately mimic the in vivo behavior of cells is an
essential step for improving the predictive accuracy of the
drug  discovery  process  [2].  Evidence  suggests  that
modification of cell growth conditions can radically influence
the behavior of cells in response to chemical reagents [3].
Many important studies have been done on cell proliferation,
differentiation, and function in vitro; however, experience
with cells in a flat tissue culture flask is different from the
complexities  of  tissues  within  the  body.  In  tissues,  cells
connect to each other as well as to the extracellular matrix
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(ECM), which is a key regulator of normal homeostasis and
tissue phenotype [1]. Receptor complexes on the surface of
cells  facilitate  interactions  with  their  neighbors,  with  the
ECM, and with other exogenous factors to enable cells to
interpret the multitude of biochemical and physical cues from
the immediate environment. The metastatic potential of tumor
cells is believed to be regulated by interactions between the
tumor cells and their extracellular environment (i.e., ECM).
These interactions can be modified by the accumulation of
genetic  changes  and  by  the  transient  alterations  in  gene
expression induced by the local tumor microenvironment [4].
Given this intricate mechanical and biochemical interplay;
important  biologic  properties  may  be  missed  if  cells  are
studied within an in vitro culture system [5]. It has also been
suggested that many important signals, key regulators, and
tissue phenotypes are lost when cells are cultured on substrates
such as culture plates [6]. Therefore, developing an in vitro
model of a tumor that in many aspects would resemble an
actual tumor to obtain a realistic assessment of drug efficacy
before their testing in animal models or patients is important
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1361[7]. Based on previous reports [7] we hypothesized that the
cells  grown  with  poly(D,L)-lactide-co-glycolide  (PLGA)–
gelatin microparticles behave differently than cells grown
without  PLGA–gelatin  microparticles  because  of  the
structural, molecular, and genetic variations in cells grown in
two  different  structural  configurations.  We  selected  three
model  anticancer  drugs  (doxorubicin,  carboplatin,  and
etoposide), which are currently used in clinical practice for
the  treatment  of  retinoblastoma,  and  drug-loaded
nanoparticles to determine the drug efficacy in both models.
We studied drug diffusion and cellular uptake to understand
the discrepancy in drug efficacy in cells grown with or without
PLGA–gelatin  microparticles.  In  addition  we  studied  the
influence  of  microparticles  on  ECM  synthesis  and  whole
genome  miRNA-microarray  profiling  to  identify  3-D-
responsive genes that have been implicated in oncogenesis,
survival, and growth of in vivo tumor.
METHODS
Materials: PLGA (copolymer ratio 50:50, molecular weight
[MW]=34,000 Da, inherent viscosity=0.41) was purchased
from  Birmingham  polymers,  Inc.  (Birmingham,  AL).
Carboplatin,  doxorubicin  hydrochloride  (DOXHCL),
etoposide, polyvinyl alcohol (PVA; average MW 30,000–
70,000 Da), BSA (fraction V), sucrose, chitosan from crab
shells (85% deacetylated), and gelatin were purchased from
Sigma-Aldrich (St. Louis, MO). All other chemicals used
were of analytical grade obtained from Sigma-Aldrich. Media
and fetal bovine serum (FBS) were purchased from Gibco-
BRL (Rockville, MD). Y79 cells were cultured in RPMI 1640
medium  (Biocolor  Ltd,  County  Antrim,  UK).  The  Sircol
Soluble Collagen Assay kit was purchased from Biocolor Ltd.
TRIZOL reagent was purchased from Invitrogen (Carlsbad,
CA). TURBO DNase was purchased from Ambion (Genetix
Biotech Asia Pvt. Ltd., New Delhi, India).
Preparation of different drug-loaded nanoparticles:
Carboplatin-loaded  nanoparticles—Nanoparticles
containing carboplatin (CNPs) were prepared as decribed by
Parveen et al. [8]. Briefly, an aqueous solution of 2 ml sodium
alginate  (0.625  mg/ml)  was  added  dropwise  into  8  ml  of
chitosan solution (0.5 mg/ml dilute solution of HCl, with pH
adjusted to approximately 5.5 with 0.1 M NaOH) containing
carboplatin  (1.25  mg).  After  overnight  stirring  of  the
emulsion, the CNPs were recovered by ultracentrifugation
(Sorvall Ultraspeed Centrifuge; Kendro, Asheville, NC) at
30,000× g for 30 min at 4 °C. The nanoparticles were formed
as  a  result  of  the  interaction  between  negative  groups  of
alginate and positively charged amino groups of chitosan. The
pellets  were  dispersed  in  double-distilled  water  and
lyophilized (LYPHLOCK 12; Labconco, Kansas City, MO)
for 48 h and then stored at 4 °C for further studies.
Etoposide-loaded  nanoparticles—Etoposide-loaded
nanoparticles  (ENP)  were  formulated  by  using  the  single
emulsion–solvent  evaporation  technique.  In  this  method,
etoposide (equivalent to 10% weight [w]/w dry weight of
polymer) was dissolved in 3 ml organic solvent (chloroform)
containing 90 mg of polymer (PLGA) to form a primary
emulsion. The emulsion was further emulsified in an aqueous
PVA solution (12 ml, 5% w/volume [v]) to form an oil-in-
water emulsion. The emulsification was performed using a
microtip probe sonicator (VC 505; Vibracell Sonics, Newton,
CT) at 39 W of energy for 2 min in an ice bath. The emulsion
was stirred using a magnetic stirrer overnight to evaporate the
organic  solvent.  The  resultant  nanoparticles  were
ultracentrifuged at 125,000× g for 20 min at 4 °C with twice
washing with double-distilled water to remove the excess
amount of PVA and unencapsulated etoposide. The obtained
particles  were  resuspended  in  double-distilled  water  and
lyophilized for 48 h to obtain the powder form and then stored
at 4 °C for further use.
Doxorubicin-loaded  nanoparticles—Doxorubicine-
loaded nanoparticles (DNP) were prepared by using the single
emulsion–solvent evaporation technique. In brief, a solution
of 100 mg of PLGA polymer and 10 mg of doxorubicin (DOX)
in 3 ml of 12.5% (v/v) methanol in chloroform solution was
emulsified in 12 ml of 2% w/v aqueous solution of PVA to
form  an  oil-in-water  emulsion.  The  emulsification  was
performed using a microtip probe sonicator set at 55 W of
energy output for 2 min over an ice bath. The emulsion was
stirred overnight at room temperature on a magnetic stirring
plate  to  allow  evaporation  of  the  organic  solvent  and
formation  of  DNPs.  DNPs  were  recovered  by
ultracentrifugation at 125,000× g for 20 min at 4 °C, washed
twice with double-distilled water to remove unbound PVA
and unencapsulated drug, and then lyophilized for 2 days to
obtain  the  powdered  DNPs.  The  lyophilized  DNPs  were
stored at 4 °C until further use.
Formulation of gelatin microparticles: PLGA microparticles
were prepared by the solvent evaporation method with slight
modifications [9]. In brief, 800 μl of an aqueous phase (W1)
was  prepared  with  BSA  (2.5%  w/v),  sucrose  (10%  w/v),
chitosan (1.25% w/v), gelatin (5% w/ v), and PVA (5% w/v)
and emulsified with polymer solution (O; 200 mg PLGA in
4 ml of dichloromethane), using an homogenizer (Biospec
Product Inc., Bartlesville, OK) at 80× g to form an oil-in-water
primary emulsion. The resultant primary emulsion was added
dropwise into a 1% w/v aqueous solution of PVA containing
10% w/v sucrose (W2) under constant magnetic stirring on a
stirring plate to form a multiple emulsion (W1/O/W2). The
emulsion was stirred overnight on a magnetic stir plate to
evaporate the organic solvent. The resultant microparticles
were recovered by centrifugation at 15,000× g, washed three
times with distilled water, and then lyophilized for 48 h the
lyophilized microparticles were stored at 4 °C until further
use.
Characterization  of  different  drug-loaded  nanoparticles:
Mean particle size and size distribution of the different drug-
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1362loaded nanoparticles were determined by using a Malvern
Zeta-sizer  Nano  ZS  (Malvern  Instrument,  Malvern,
Worcestershire, UK) based on quasi-elastic light scattering.
Briefly, approximately 1 mg/ml of different formulations of
the nanoparticle solutions were prepared in double-distilled
water and sonicated for 30 s in an ice bath. Size measurements
were performed in triplicate following the dilution (100 ml
diluted to 1 ml) of the NP suspensions in MilliQ water at 25 °C.
The Zeta potential was measured in the same instrument at
25  °C  using  the  above  protocol.  All  measurements  were
performed in triplicate.
Characterization of gelatin microparticles: The shape and
surface  morphology  of  gelatin  microparticles  were
characterized by scanning electron microscopy (SEM, Hitachi
S-3400N;  Hitachi  High-Technologies,  Krefeld,  Germany).
The powdered microparticles were attached to a brass stub
TABLE 1. LIST OF PRIMERS USED FOR REAL TIME QUANTITATIVE RT–PCR.
Gene name Primer sequences Tm
ABCC6 FP 5′TTGGATTCGCCCTCATAGTC 3′ 65 °C
  RP 3′GGTAGCTGGCAAGACAAAGC 5′  
HMGA2 FP 5′GGCCAGCTCATAAAATGGAA 3′ 61 °C
  RP 3′TACTGTTCCATTGGCCACAA 5′  
MMP9 FP 5′TTGACAGCGACAAGAAGTGG 3′ 64 °C
  RP 3′GCCATTCACGTCGTCCTTAT 5′  
ABCA3 FP 5′AGGAAAGGAGGCTGAAGGAG 3′ 65 °C
  RP 3′GTGCTGACCATGAAGCTGAA 5′  
ERBB3 FP 5′GCCAATGAGTTCACCAGGAT 3′ 64 °C
  RP 3′ACGTGGCCGATTAAGTGTTC 5′  
BCL2 FP 5′GGATGCCTTTGTGGAACTGT 3′ 63 °C
  RP 3′AGCCTGCAGCTTTGTTTCAT 5′  
MYCN FP 5′CTTCGGTCCAGCTTTCTCAC 3′ 64 °C
  RP 3′GTCCGAGCGTGTTCAATTTT 5′  
APAF-1 FP 5′TTCTGATGCTTCGCAAACAC 3′ 63 °C
  RP 3′CTGGCAAATCTGCCTTCTTC 5′  
CDKN2A FP 5′ATATGCCTTCCCCCACTACC 3′ 67 °C
  RP 3′CCCCTGAGCTTCCCTAGTTC 5′  
CDKN1A FP 5′ATGAAATTCACCCCCTTTCC3′ 65 °C
  RP 3′CCCTAGGCTGTGCTCACTTC5′  
PDCD2 FP 5′GCATTGCCACCATAAATCCT3′ 63 °C
  RP 3′GCAGTTTCCCATATGGTGCT5′  
Figure 1. This figure shows the size distribution of different drug-loaded nanoparticles measured by dynamic light scattering analysis. A:
Etoposide loaded nanoparticles (ENPs) showing an average diameter of 256 nm. B: Carboplatin loaded nanoparticles (CNPs) showing an
average diameter of 507 nm. C: Doxorubicin loaded nanoparticles (DNPs) showing an average diameter of 249 nm.
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1363through double adhesive tape and were gold coated using a
sputter gold coater at 20 KV (Hitachi, E-1010, Ion Sputter;
Hitachi High-Technologies). The stub was fixed in a sample
holder and placed in the vacuum chamber of the SEM (Hitachi
S-3400N; Hitachi High-Technologies) and observed under
low vacuum. The average particle diameters of microparticles
were determined from the SEM picture.
Cell  culture  and  cell  seeding  for  gelatin  microparticle
composition optimization: Y79 cells RCB1645 were obtained
from the RIKEN cell bank (Ibaraki, Japan) and maintained in
RPMI-1640  media  supplemented  with  10%  FBS  and  1%
penicillin streptomycin in T-75 cm2 flasks in an incubator
(Thermo Electron Corporation, Asheville, NC) at 37 °C and
5% CO2. Fresh retinoblastoma tumor cells were isolated from
RB-enucleated  eyeballs  (Vision  Research  Foundation,
Sankara Nethralaya, Chennai, India) and cultured as described
above. All samples were collected with the approval of the
institutional  review  board  at  VRF  (Vision  Research
Foundation)  and  in  accordance  with  the  Declaration  of
Helsinki.  Each  formulation  of  PLGA  microparticles  was
weighed (approximately 2 mg/ml) and soaked for 3 h at 37 °C
in 70% alcohol. Microparticles were centrifuged to remove
alcohol and washed twice with media. Fifty percent FBS was
added, and the solution was kept in a CO2 incubator for 3 h.
For studying the effects of microparticle composition on
cell growth, 1 ml of the microparticle suspension prepared as
above was transferred to separate wells of 6-well plates. The
medium  from  each  well  was  aspirated  carefully,  leaving
microparticles  in  the  wells  before  cell  seeding.  A  500-μl
aliquot of Y79 cell suspension (1×106 cells/ml)/fresh RB cell
suspension in RPMI 1640 medium was added directly onto
microparticles in each well. After 3 h of incubation at 37 °C
in a CO2 incubator, an additional 1.5 ml of medium was added
to each well and cells were allowed to grow in the incubator.
The medium was changed on alternate days, and cells were
counted at 7 days post seeding to determine the effect of
microparticle composition on Y79 cell growth. To study the
total number of cells grown in gelatin microparticles, the
adherence cells from a microparticle clump was recovered
after 10 days of post seeding. Cell detachment was done by
treating the microparticles with 1 ml of 0.1 M citrate buffer
containing  0.1%  crystal  violet  for  1  h  at  37  °C.  After
detachment, the total number of cells grown with a different
formulation of microparticles was counted separately using a
hemocytometer.  Photomicrographs  of  selected  plates  with
cells  attached  to  microparticles  were  taken  with  a  phase-
contrast inverted microscope fitted with a digital camera. The
fluorescent  images  of  Y79/RB  cells  labeled  with
CellTracker™  CM-DiI  reagent  (Molecular  probes,
Figure 2. This figure shows the scanning
electron  microscope  picture  of  a
Poly(D,L-lactide-co-glycolide)
(PLGA)  scaffold  microparticle
containing  1.25%  chitosan  and  5%
gelatin  (100  mg  PLGA,  1.25  mg
chitosan,  and  5  mg  gelatin).  Surface
morphology  of  microparticles  was
characterized  by  scanning  electron
microscopy  (SEM).  The  average
diameter of formulated microparticle in
this study ranged from 145 μm to 162
μm.
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1364Invitrogen, Bangalore, India) grown with the scaffold were
captured.
Antiproliferative effects of anticancer drugs and drug-loaded
nanoparticles: The antiproliferative effects of drugs, both in
the native form and encapsulated inside nanoparticles, were
analyzed using the methodology of Horning et al. [7]. For this
study  the  Y79/RB  cells  were  allowed  to  grow  in  a  2-D
suspension  (tissue  culture-treated  Petri  dishes)  and  a  3-D
model  (in  microparticles).  The  tissue  culture-treated  Petri
dishes (100 mm×20 mm; #353003; Becton Dickson, Franklin
Lakes, NJ) taken for the 2-D study provided more surface area
for cells to grow without reaching confluency. For the 3-D
model, nontissue culture Petri dishes (100 mm×15 mm; #08–
757–13; Fisher Scientific, Mumbai, India) were used; these
enabled  better  cellular  attachment  and  growth  onto
microparticles compared to the surface of a Petri dish. Cell
seeding in the case of the 2-D monolayer was performed the
second day post seeding on microparticles at a cell density of
0.5×106 cells/ml. This protocol for cell seeding and growth
was optimized to obtain approximately the same cell count in
both sets of experiments at the time of drug treatment for a
better comparison of drug efficacy. Three model anticancer
drugs,  i.e.,  doxorubicin,  carboplatin  and  etoposide,  were
selected to determine their IC50 values in Y79/RB cells grown
on 2-D as well as 3-D models. The chosen drugs are currently
being used in the treatment of retinoblastoma and are well
known  DNA  intercalating  anticancer  agent.  For  the  cell
toxicity study the stock solutions of drugs were prepared in
DMSO and diluted appropriately in tissue culture medium to
obtain the desired concentration [8]. Similarly, equivalent
concentrations  of  drug  encapsulated  in  nanoparticles
(doxorubicin  and  etoposide  in  PLGA  nanoparticles,
carboplatin  in  chitosan  nanoparticles)  were  prepared  with
RPMI medium. On day 5 of post seeding, media was carefully
removed and replaced with 5 ml of media containing different
concentrations of drugs and drug-loaded nanoparticles. After
48 h the treated cells (2-D and 3-D culture) were collected and
filtered through 35 µm nylon mesh to separate cells from
microparticles. The detached cells were stained using 0.4%
(w/v)  trypan  blue  in  deionized  water,  and  viable  cells
(unstained) were counted using a hemocytometer.
Collagen  assay:  Collagen  content  was  assayed  using  the
manufacturer’s protocol. Cells with/without PLGA–gelatin
microparticles  were  suspended  in  PBS  (137  mM  NaCl,
2.7  mM  KCl,  10  mM  sodium  phosphate  dibasic,  2  mM
potassium  phosphate  monobasic  and  a  pH  of  7.4).  The
preparations were centrifuged at 80× g using an Eppendorf
microcentrifuge  (5417R;  Eppendorf-Netheler-Hinz-GmbH,
Hamburg, Germany), and the sediment was treated with 1 ml
of 0.5 M acetic acid for 18 h at 4 °C. One milliliter of the dye
reagent supplied with the assay kit was added to 100 μl of the
acid extract in 1.5 ml Eppendorf tubes and mixed gently for
30 min at room temperature. The collagen-bound dye complex
was recovered after centrifugation at 7,800 ×g for 10 min as
above. The complex was solubilized in 1 ml of the alkali
reagent provided with the assay kit. The absorbance of the
samples was measured at 550 nm using a microwell plate
reader (Fisher Biotech, Pittsburgh, PA). A standard plot of
collagen  was  prepared  under  similar  conditions.  Either
microparticles without cells or PBS was used as controls. The
amount of collagen present in the native microparticles was
deduced from the actual collagen amounts obtained in 2-D and
3-D  culture  experiments.  Therefore  the  there  was  no
interference of the polymer used in microparticles in the assay.
Recovery  of  cells  from  poly(D,L)-lactide-co-glycolide–
gelatin  microparticles  following  freezing:  To  determine
whether the cells grown in the 3-D model could be rescued
after freezing, microparticles were seeded (seeding density)
0.5×106 cells/mg of microparticles) and cultured as above in
noncell culture Petri dishes for 5 days. Cells with PLGA–
gelatin  microparticles  were  washed  with  RPMI-1640
medium,  resuspended  in  1  ml  of  cryopreservation  media
(DMSO, 10%; FBS, 90%), transferred into cryovials, and then
frozen in liquid nitrogen. After 24 h of freezing, cells were
thawed and the entire content of each cryovial was transferred
into Petri dishes and recultured for 48 h in RPMI medium.
Cells with PLGA–gelatin microparticles cultured as above for
the same time period but not subjected to the freezing step,
were  used  as  the  control.  Cells  cultured  without  PLGA–
gelatin microparticles (0.5×106 cells/ml of cryopreservation
media) were also frozen and recultured as above. Cell viability
for each sample was determined using trypan blue as above.
The  percentages  of  cells  with  or  without  PLGA–gelatin
microparticles rescued were calculated from the cell numbers
with and without the freezing step.
Flow cytometry: Doxorubicin was used for this study because
of its inherent fluorescent property. Fluorescent intensity as a
measure of drug uptake by cells with or without PLGA–
gelatin microparticles was determined using a FACSCalibur
flow cytometer (Becton Dickson) at 488 nm excitation and a
585/42 filter (564–606 nm) to match the emission spectra of
doxorubicin. On day 5 post seeding, media were carefully
removed and 5 ml of doxorubicin solution (2,500 ng/ml) was
added to each Petri dish and placed at 37 °C for 4 and 8 h each
with triplicates. Cells were trypsinized from microparticles
and  monolayered  as  described  above,  centrifuged,  and
resuspended into a single cell suspension in DPBS + 2% FBS
at concentrations of either 2×106 cells/ml or 1×106 cells/ml.
The cell suspensions containing microparticles were filtered
twice through a 35-μm nylon mesh tube cap into a 12×75 mm
round-bottom tube (#352235; Becton Dickson) to remove
microparticles from the cell suspension.
Oligonucleotide arrays: Total RNA used for the microarray
analysis  was  isolated  from  cultured  cells  using  TRIZOL
reagent and treated with TURBO DNase to remove the DNA
contamination. The RNA samples (10 μg each) in a 50-μl
reaction were treated with 1 μl of TURBO DNase (2 U) in 1×
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1365TURBO DNase buffer at 37 °C for 30 min. After incubation,
the RNA sample was extracted with phenol–chloroform to
inactivate  the  TURBO  DNase.  Agilent's  Low  RNA  Input
Linear  Amplification  Kit  PLUS  (Agilent  Technologies
Genotypic, Bangalore, India) was used to generate fluorescent
complementary RNA (cRNA). This method uses T7 RNA
polymerase,  which  simultaneously  amplifies  the  target
material  and  incorporates  cyanine  3-labeled  cytidine  tri-
phosphate.  Qiagen’s  RNeasy  mini  spin  columns  (Qiagen,
New Delhi, India) were used for purification of the amplified
cRNA samples, and the samples were then hybridized to the
Human Whole Genome 44K Oligo Microarray for 17 h at
65  °C,  as  recommended  by  the  manufacturer  (Agilent
Technologies). Data analysis was done using Genespring GX
Figure 3. This figure shows the growth
kinetics  of  Y79  cells  with  different
seeding densities (104 to 105 cells) co-
cultured with a gelatin scaffold for 20
days.  The  cells  were  harvested  and
counted on 2nd, 5th, 8th, 15th, and 20th
day. The Y79 growth kinetics results on
gelatin microparticle demonstrated the
composition  of  formulated
microparticle facilitated profound Y79
cell proliferation.
Figure 4. This figure shows the growth
kinetics of Y79 cells co-cultured with
microparticles formulated with different
concentrations of gelatin (3% and 5%
gelatin). The graph shows increased cell
concentrations on 15th and 20th. Day of
Y79  cell  culture  on  microparticles
coated with 5% gelatin (p<0.01) when
compared to that of 3% gelatin coated
microparticles 0.01).
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1366version  10  (Agilent  Technologies).  Agilent  Feature
Extraction software (G25677AA; Agilent Technologies) was
used to analyze the microarray data. Two biologic replicates
were used for gene expression microarray analysis.
MicroRNA isolation and expression analysis:
RNA extraction—Total RNA was isolated using TRI-
Reagent  (Ambion,  Austin,  TX).  RNA  concentration  and
purity were quantified using a Nanodrop (Nanodrop, Santa
Clara, CA) spectrophotometer with the nanodrop ribogreen
assay, and the quality of the total RNA was determined on an
Agilent bioanalyzer (Agilent, Santa Clara, CA).
MicroRNA array hybridization and detection—Two
biologic  replicate  samples  were  used  for  the  miRNA
microarray  analysis.  Human  miRNA  V2  8×15k  Agilent
arrays,  which  represent  723  human  and  76  human  viral
miRNAs, were used for the miRNA analysis. Total RNA
underwent  phosphatase  treatment.  The  3′  end  of  the
dephosphorylated RNA was ligated with one molecule of
cyanine  3-cytidine  bisphosphate  (3-pCp),  as  this  reagent
selectively labels and hybridizes mature miRNAs with greater
than 30% efficiency. A hybridization cocktail was added to
the  arrays,  and  hybridization  was  performed  in  the
hybridization oven set at 55 °C for 20 h. The microarrays were
washed using Agilent wash buffer. Scanning and extraction
was performed using Agilent feature extraction software. The
study was done in three biologic replicates. Data analysis was
done  using  Genespring  GX  version  10.  Agilent  Feature
Extraction software (G25677AA) was used to analyze the
microarray data. The sum of background-subtracted signals
for each repeated miRNA was calculated and log transformed
to log base 2. The cut off was greater than 1 (log-transformed
value) and less than 1 (log-transformed value).
Real-time  quantitative  reverse-transcriptase  (RT)-
PCR—RNA was extracted by the guanidine isothiocyanate
and  chloroform  method  (TRI  Reagent;  Sigma-Aldrich,
Bangalore, India). All RNA samples were treated with DNase
(Turbo;  Ambion,  Genetix  Biotech  Asia  Pvt.  Ltd).  For  all
samples, 1 μg of total RNA was used to synthesize first-strand
cDNA with reverse transcriptase (SuperScript II; Invitrogen,
Joyvel,  Chennai,  India)  and  random  primers.  The  cDNA
synthesis  was  performed  at  37  °C  for  60  min  after  heat
inactivation at 95 °C for 10 min. The primer sequences of the
selected genes from the microarray are listed in Table 1. PCR
was  performed  using  1×  SYBR  Green  PCR  Master  Mix
(Applied Biosystems, Lab India, Chennai, India) on a real-
time PCR system (Prism 7300; Applied Biosystems). Cycling
conditions were as follows: 2 min at 50 °C, 10 min at 95 °C,
and 40 cycles of 15 s at 95 °C, plus 1 min at 60 °C. Commercial
software  (SDS  ver.2.3;  Applied  Biosystems)  was  used  to
calculate ΔΔCt relative expression values for all the genes
studied, normalized to the GAPDH endogenous control.
Statistical  analysis:  The  statistical  analysis  included  the
independent Student t test. Statistical analysis was performed
using SPSS version 12.0 software (Chicago, IL). P values less
than 0.05 were considered significant.
RESULTS
Characterization of different drug-loaded nanoparticles: The
size distribution and surface charge of different drug-loaded
Figure 5. This figure shows the phase
contrast  and  fluorescent  microscope
images of Y79 cells grown on Poly(D,L-
lactide-co-glycolide)  (PLGA)  scaffold
microparticles.  A:  Phase  contrast
microscope  picture  of  Gelatin-coated
PLGA  microparticles  under  10×
magnification.  B:  Phase-contrast
images  showing  cells  attached  to  the
microparticles  (white  arrows  pointing
Y79  cells  attached  to  microparticles)
forming  a  three-dimensional  growth
over  the  microparticles  under  10×
magnification.  C:  Phase  contrast
microscopic  image  of  3-D  growth  of
Y79 cells over scaffold microparticles
(black  arrow  pointing  to  Y79  cells
attaché  to  microparticles)  under
40×  magnification.  D:  Fluorescent
microscopic  image  showing  the  3-D
growth  of  Y79  cells  (labeled  with
Celltracker  dye)  over  scaffold
microparticle  (white  arrows  pointing
Y79  cells  attached  to  microparticle)
under 40× magnification.
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1367nanoparticles  were  measured  by  dynamic  light  scattering
analysis. This study revealed that ENPs, CNPs, and DNPs
have an average diameter of 256 nm, 507 nm, and 249 nm,
respectively, as shown in Figure 1 and have an average Zeta
potential of −13 mV, –36 mV, and −5.56 mV, respectively.
Formulation and characterization of poly(D,L)-lactide-co-
glycolide microparticles: In the current study, we prepared a
3-D tumor model with PLGA–gelatin microparticles for in
vitro  evaluation  of  different  anticancer  drugs  (native  and
loaded in nanoparticles). It was previously well documented
that  gelatin  is  a  suitable  candidate  for  scaffold  materials
because  of  its  biocompatibility,  low  immunogenicity,  and
biodegradability. Gelatin contains Arg–Gly–Asp (RGD)-like
sequences  that  promote  cell  adhesion  and  migration  by
forming a polyelectrolyte complex. Furthermore, the anionic
cell  surface  provided  by  the  gelatin–chitosan-blended
microparticles  provide  better  cell  adhesion  and  cellular
bioactivity for proliferating cells. A successful microparticle
formulation was achieved with a highly porous matrix to
facilitate the infiltration of proliferating cells. As evidenced
from the SEM image, the formulated microparticle showed a
porous infrastructure with interconnected void structures and
had a spherical shape covered with a thin film of polymer
(Figure 2). This rough surface could be due to deposition of
cationic chitosan on the anionic microparticle surface, which
is apparent from the surface characteristics [7]. Similarly,
particle size is an important parameter that could affect the
degradation  of  the  polymer  matrix  [10].  To  achieve  a
microparticle  of  a  desired  diameter,  the  conditions  for
emulsification and formulation composition were optimized.
The average diameter of the formulated microparticle in this
study ranged from 145 μm to 162 μm.
Effect of composition of the scaffold and influence of cell
seeding density on Y79 cell growth: We studied the effect of
gelatin concentration (used in microparticle composition) on
the proliferation of Y79 cells. The Y79 growth kinetic results
on  the  gelatin  microparticle  demonstrated  that  the
composition  of  the  formulated  microparticle  facilitated
profound Y79 cell proliferation (Figure 3). It was further seen
that  the  microparticles  formulated  with  a  higher  gelatin
content (5% w/v) demonstrated better cell growth than those
formulated with a lower gelatin content (3% w/v; Figure 4).
Therefore, PLGA microparticles fabricated with 5% gelatin
were chosen as a suitable formulation for further studies.
The  optimized  composition  of  microparticles,  which
consisted of 5% gelatin and 1.25% chitosan, demonstrated cell
growth from an initial seeding cell density of 0.05×106 to a
cell density of 0.4×106 cells/mg of microparticles, which is an
eightfold increase in cell density after 6 days of culture. Cells
attached more to the microparticles rather than to the surface
of the nontissue culture Petri dish. Initially, cells were seen
attached  to  the  microparticle  surface,  and  with  time  cells
engulfed the microparticles completely, forming a 3-D tumor-
like structure (Figure 5A-C phase contrast and Figure 5D
fluorescence-labeled Y79 cells). Either a single microparticle
Figure  6.  This  figure  shows  the
comparison  of  post  freeze  and  thaw
viability of Y79 cells between Y79 cell
culture  without  microparticles  (2-D)
and  Y79  cells  co-cultured  with
microparticles (3-D). The bar diagram
shows the viability of Y79 cultured cells
with  (3-D)  and  without  (2-D)
microparticles retrieved from freezing.
The  Y79  cells  viability  was  slightly
higher in 3-D model compared to that in
2-D  monolayer  (41%  versus  35%).
Error bars represent standard deviation
obtained from triplicates.
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1368Figure 7. This figure shows the anti-proliferative effect of drug loaded nanoparticles on Y79 cells cultures in Two-dimensional (2-D) or three
dimensional (3-D) patterns. A: Y79 cells co-cultured with microparticles (3-D) shows decreased sensitivity (p<0.001) to native carboplatin
when compared to Y79 cells cultured without microparticles (2-D). B: Y79 cells co-cultured with microparticles (3-D) shows decreased
sensitivity (p<0.0001) to Carboplatin loaded nanoparticles when compared to Y79 cells cultured without microparticles (2-D). C: Y79 cells
co-cultured with microparticles (3-D) shows decreased sensitivity (p<0.001) to native etoposide when compared to Y79 cells cultured without
microparticles (2-D). D: Y79 cells co-cultured with microparticles (3-D) shows decreased sensitivity (p<0.001) to etoposide-loaded Np when
compared to Y79 cells cultured without microparticles (2-D). E: Y79 cells co-cultured with microparticles (3-D) shows decreased sensitivity
(p<0.001)  to  native  doxorubicin  when  compared  to  Y79  cells  cultured  without  microparticles  (2-D).  F:  Y79  cells  co-cultured  with
microparticles (3-D) shows decreased sensitivity (p<0.001) to doxorubicin loaded nanoparticles when compared to Y79 cells cultured without
microparticles (2-D). G: Fresh retinoblastoma tumor cells co-cultured with microparticles (3-D) shows decreased sensitivity (p<0.001) to
native carboplatin when compared to Y79 cells cultured without microparticles (2-D). H: Fresh retinoblastoma tumor cells co-cultured with
microparticles (3-D) shows decreased sensitivity (p<0.0001) to native etoposide when compared to Y79 cells cultured without microparticles
(2-D). I: Fresh retinoblastoma tumor cells co-cultured with microparticles (3-D) shows decreased sensitivity (p<0.001) to native doxorubicin
when compared to Y79 cells cultured without microparticles (2-D). Error bars represent standard deviation obtained from triplicates.
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1369or a cluster of two to three microparticles were witnessed to
form the 3-D tumor-like structure.
Extracellular matrix synthesis and retrieval of cells from a
three-dimensional model following freezing: After 5 days of
growth, cells in the 3-D model synthesized 59.8±1.2 µg of
collagen per 1×106 cells, which was significantly higher than
the 25.29±0.7 µg of collagen synthesized for the same number
of cells in the 2-D monolayer (p<0.05, n=5). Following the
freezing step, cell viability was slightly higher in the 3-D
model compared to that in the 2-D monolayer (41% versus
35%; Figure 6).
Antiproliferative  activity  of  drugs  and  drug-loaded
nanoparticles on Y79 cells grown with or without a scaffold:
Cytotoxicity of model anticancer drugs was determined in
Y79/RB  cells  grown  with  or  without  PLGA–gelatin
microparticles following 48 h of drug treatment. Cell numbers
were similar in both models at the time of treatment, and the
inhibition  in  cell  growth  was  calculated  according  to  the
respective untreated controls. IC50 values of drugs and drug-
loaded nanoparticles were significantly higher in Y79 cells
with  PLGA–gelatin  microparticles  than  in  cells  grown
without  PLGA–gelatin  microparticles  (Figure  7).  The
differences in the IC50 values observed were 4.5 to 21.8 fold
depending  upon  the  drug  and  drug-loaded  nanoparticles
(Table 2). Similarly, we observed significantly higher IC50
values of native drugs in RB tumor cells with PLGA–gelatin
microparticles compared to RB cells grown without PLGA–
gelatin microparticles (Figure 7G-I). The differences in the
IC50 values of native drugs in RB tumor cells observed were
2.4 to 13.4 fold (Table 2).
TABLE 2. COMPARISON OF IC50 VALUES OF RESPECTIVE NATIVE DRUGS AND DRUG LOADED NANOPARTICLES BETWEEN Y79 CELLS CO-
CULTURED WITH MICROPARTICLES (3-D0 AND Y79 CELLS CULTURED WITHOUT MICROPARTICLES (2-D).
  IC50  
Drug 2-D 3-D Fold change
Native doxorubicin 154.8 1202 7.76
Np doxorubicin 9.54 102.3 10.7
Native etoposide 17.66 159.2 9.01
Np etoposide 3.86 17.37 4.5
Native carboplatin 138 1584 11.47
Np carboplatin 28.84 630 21.84
Figure 8. This figure shows the uptake of doxorubicin drug by Y79 cells either or not co-cultured with microparticles using flow cytometry.
A: The flow cytometry histogram shows decreased uptake of drug by Y79 cells co-cultured with microparticles (3-D) when compared to Y79
cells cultured without microparticles at 4 h. B: Flow cytometry histogram shows decreased uptake of a drug by Y79 cells co-cultured with
microparticles (3-D) when compared to Y79 cells cultured without microparticles at 24 h. The x-axis represent fluorescein isothiocyanate
(FITC) intensity and the y-axis represents cell counts.
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1370Drug uptake by cells with or without poly(D,L)-lactide-co-
glycolide-gelatin  microparticles:  After  treatment  with
doxorubicin (2,500 ng/ml), significantly fewer (p<0.05) cells
with  PLGA–gelatin  microparticles  exhibited  drug  uptake
compared  to  cells  grown  without  microparticles.  The
difference in fluorescence intensity was 4.4 fold at 4 h (Figure
8A), which increased to 15.9 fold at 24 h (Figure 8B).
Microarray  analysis:  Results  of  the  cDNA  microarray
revealed  changes  in  the  expression  of  4,490  genes
(overexpression  of  2,490  genes;  downregulation  of  2,000
genes)  in  cells  grown  with  PLGA–gelatin  microparticles
compared to those grown without microparticles (Figure 9A).
Only genes with p≤0.05 and a log ratio of at least 2.0 for
upregulation  (≥1  fold)  and  a  log  ratio  of  0.5  for
downregulation (≤0.5 fold), keeping a median log ratio of 1
in both biologic replicates, were considered for expression
analysis [11]. The important upregulated (Table 3 and Table
4)  and  downregulated  (Table  5)  genes  are  provided.  We
classified the altered transcripts based on their biologic roles.
The data also identified several candidate genes that are found
to be highly overexpressed in retinoblastoma tumors and that
keep tumors in a proliferation state, such as Homo sapiens v-
myc myelocytomatosis viral-related oncogene (MYCN) [12,
13], H. sapiens jun oncogene (Jun) [11], H. sapiens v-erb-b2
(ERBB3)  [14],  and  H.  sapiens  insulin-like  growth  factor
binding protein 5 (IGFBP5) [15]. We also found enhanced
expression of collagen, integrins, fibronectin, and laminin,
which  crosslink  and  stiffen  the  tissue  stroma  to  promote
transformation,  tumor  growth,  motility,  and  invasion  and
enhance cancer cell survival [16].
MicroRNA  analysis:  Results  of  the  microRNA  analysis
revealed  changes  in  the  expression  of  52  miRNAs
(overexpression  of  6  miRNAs;  downregulation  of  46
miRNAs) in cells grown with PLGA–gelatin microparticles
compared to those grown without microparticles (Figure 9B).
The important differentially regulated miRNAs are provided
in Table 6. We classified the altered miRNAs based on their
biologic roles (oncomirs and tumor suppressors). Our data has
identified downregulated tumor suppressor miRNAs in cells
with PLGA–gelatin microparticles, such as let-7 miRNAs
(let-7  family)  and  miR-34a  (which  may  enhance
retinoblastoma tumor proliferation) [17,18] and miR-15a and
miR-16, which have been implicated in cell-cycle control and
apoptosis [19]. We also identified upregulated miRNAs, such
as miR-198, which may play significant roles in regulating
retinoblastoma tumor genesis [20]; miR-18a and miR-19b,
which are upregulated in various carcinomas and increased
expression  of  this  cluster  contributes  to  cancer  formation
[21]; and miR-106a, which is a potential biomarker in the
diagnosis of gastric carcinoma [22].
Figure 9. This figure represents microarray heat map displaying deregulated genes and microRNAs in Y79 cells either or not co-cultured with
microparticles. A: Heat map shows significantly upregulated and down-regulated genes in Y79 cells co-cultured with microparticles (3-D)
when compared with Y79 cells cultured without microparticles (2-D). B: Heat map shows significantly upregulated and down-regulated
microRNAs in Y79 cells co-cultured with microparticles (3-D) when compared with Y79 cells cultured without microparticles (2-D). Green
color represents upregulated genes or microRNAs and red color represents down-regulated genes or microRNAs. Heat map shows gene IDs
or microRNA names and their respective expression fold changes in Y79 cells co-cultured with microparticles (3-D) when compared with
Y79 cells cultured with microparticles (2-D).
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1371TABLE 3. SHOWING THE UPREGULATED GENES IN Y79 CELLS GROWN WITH MICROPARTICLES COMPARED TO CELLS WITHOUT MICROPARTICLES.
Gene ID Gene name Chromosome
location
Fold change significant p-value
<0.05
Category
COL2A1 Homo sapiens collagen, type II, alpha 1 [NM_001844] chr12 3.9837 0.0007 Extracellular matrix
protein
COL1A1 H.sapiens mRNA for prepro-alpha1(I) collagen. [Z74615] 17q21.33 1.1663 0.0026 Extracellular matrix
protein
COL1A2 Homo sapiens collagen, type I, alpha 2 (COL1A2), mRNA
[NM_000089]
7q21.3 1.5104 0.0496 Extracellular matrix
protein
COL13A1 Homo sapiens collagen, type XIII, alpha 1 [NM_005203] chr10 3.2391 0.0337 Extracellular matrix
protein
COL5A3 Homo sapiens collagen, type V, alpha 3 [NM_015719] chr19 1.6284 0.0145 Extracellular matrix
protein
COL16A1 Homo sapiens collagen, type XVI, alpha 1 [NM_001856] chr1 1.4568 0.0005 Extracellular matrix
protein
COL13A1 Homo sapiens collagen, type XIII, alpha 1 [NM_005203] chr10 1.3769 0.0337 Extracellular matrix
protein
COL23A1 Homo sapiens collagen, type XXIII, alpha 1
[NM_173465]
chr5 1.206 0.0033 Extracellular matrix
protein
COL18A1 Homo sapiens collagen, type XVIII, alpha 1
[NM_030582]
chr21 1.1288 0.0058 Extracellular matrix
protein
ITGB4 Homo sapiens integrin, beta 4 [NM_000213] chr17 1.6027 0.0008 Extracellular matrix
protein
CIB2 Homo sapiens calcium and integrin binding family member
2 [NM_006383]
chr15 1.1749 0.0001 Extracellular matrix
protein
ITGA2 Homo sapiens integrin, alpha 2 [NM_002203] chr5 1.1054 0.0036 Extracellular matrix
protein
FNDC4 Homo sapiens fibronectin type III domain containing 4
[NM_022823]
chr2 1.2791 0.005 Extracellular matrix
protein
LAMC2 Homo sapiens laminin, gamma 2 [NM_005562] chr1 1.0315 0 Extracellular matrix
protein
MYCN Homo sapiens v-myc myelocytomatosis viral related
oncogene, neuroblastoma derived (avian) [NM_005378]
chr2 1.271 0.0003 oncogene
JUN Homo sapiens jun oncogene [NM_002228] chr1 1.108 0.0002 oncogene
BCL2 Human B-cell leukemia/lymphoma 2 (bcl-2) proto-
oncogene [M13995]
chr18 1.2855 0.0007 oncogene
ERBB3 Homo sapiens v-erb-b2 erythroblastic leukemia viral
oncogene homolog 3 (avian) [NM_001982]
chr12 1.03 0.0148 oncogene
MAFA Homo sapiens v-maf musculoaponeurotic fibrosarcoma
oncogene homolog [NM_201589]
chr8 1.3354 0.0009 oncogene
ERG Homo sapiens v-ets erythroblastosis virus E26 oncogene
homolog (avian) [NM_004449]
chr21 1.421 0.0185 oncogene
RAB34 Homo sapiens RAB34, member RAS oncogene family
[NM_031934]
chr17 3.3803 0.0001 oncogene
RAB37 Homo sapiens RAB37, member RAS oncogene family
[NM_175738]
chr17 2.695 0.0017 oncogene
RAB31 Homo sapiens RAB31, member RAS oncogene family
[NM_006868]
chr18 2.2873 0.0051 oncogene
RAB13 Homo sapiens RAB13, member RAS oncogene family
[NM_002870]
chr1 1.5812 0.0182 oncogene
RAB26 Homo sapiens RAB26, member RAS oncogene family
[NM_014353]
chr16 1.4142 0.0004 oncogene
LCN2 Homo sapiens lipocalin 2 (oncogene 24p3) [NM_005564] chr9 1.2526 0.0029 oncogene
KRAS Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog, mRNA (cDNA clone IMAGE:
5301134). [BC029545]
chr12 1.3272 0.0059 oncogene
RAB9B Homo sapiens RAB9B, member RAS oncogene family,
[BC018033]
chrX 1.1607 0.0197 oncogene
RAB32 Homo sapiens RAB32, member RAS oncogene family
[NM_006834]
chr6 1.102 0.0124 oncogene
RAB36 Homo sapiens RAB36, member RAS oncogene family
[NM_004914]
chr22 1.101 0.0043 oncogene
RAB31 Homo sapiens RAB31, member RAS oncogene family
[NM_006868]
chr18 1.0456 0.0051 oncogene
ABCG1 Homo sapiens ATP-binding cassette, sub-family G
(WHITE), [NM_207630]
chr21 1.3562 0.0018 ATP binding cassette
ABCG4 Homo sapiens ATP-binding cassette, sub-family G
(WHITE), [NM_022169]
chr11 1.2119 0.0006 ATP binding cassette
ABCC4 Homo sapiens ATP-binding cassette, sub-family C (CFTR/
MRP), member 4 [NM_005845]
chr13 1.0357 0.0104 ATP binding cassette
ABCA3 Homo sapiens ATP-binding cassette, sub-family A
(ABC1), [NM_001089]
chr16 1.0245 0.0012 ATP binding cassette
ABCC6 Homo sapiens ATP-binding cassette, sub-family C (CFTR/
MRP), [NM_001079528]
chr16 1.0239 0.0033 ATP binding cassette
IGFBP5 Homo sapiens insulin-like growth factor binding protein 5
(IGFBP5), mRNA [NM_000599]
chr2 1.5048 0.0001 Cell proliferation
MMP17 Homo sapiens matrix metallopeptidase 17 (membrane-
inserted) (MMP17), mRNA [NM_016155]
chr12 1.4897 0.0036 invasion
MMP 13          
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1372Real-time quantitative RT–PCR: Seven upregulated genes-
erythroblastic leukemia viral oncogene homolog 3(ERBB-3),
B-cell  leukemia/lymphoma  2  (BCL-2),  v-myc
myelocytomatosis  viral  related  oncogene,  neuroblastoma
derived  (MYCN),  ATP-binding  cassette,  sub-family  C-
member  6  (ABCC6),  High  mobility  group  AT-hook  2
(HMGA-2),  Matrix  metallopeptidase  9  (MMP-9),  ATP-
binding cassette, sub-family A-member 3 (ABCA-3) and four
down-regulated genes- Cyclin-dependent kinase inhibitor 2A
(CDKN-2),  Cyclin-dependent  kinase  inhibitor  1A
(CDKN-1A),  Programmed  cell  death  2  (PDCD-2)  and
apoptotic peptidase activating factor 1 (APAF-1)-from the
microarray  data  have  been  confirmed  by  real-time
quantitative  RT–PCR.  The  results  are  consistent  with  the
microarray data. The fold changes of all the genes studied was
only slightly higher when measured using quantitative RT–
PCR compared to the microarray fold changes, reflecting the
better dynamic range of quantitative RT–PCR (Figure 10).
DISCUSSION
Owing  to  excellent  biocompatibility  and  high  mechanical
strength,  the  biodegradable  polyester  PLGA  has  been
frequently used (as biomaterial) for drug delivery systems as
well as for tissue engineering applications. However, due to
its  hydrophobic  properties  it  is  difficult  to  wet  the
microparticles (constituent of PLGA) in cell culture medium
and hence this limits the adhesion of proliferating cells [7,
23].  To  circumvent  this  problem,  our  formulated
microparticles were coated with a hydrophilic polymer of
natural origin, i.e., gelatin. Further, with a view to promoting
better cell adhesion, we incorporated PVA in the internal
phase of the primary emulsion. Here, the amphiphilic PVA
could anchor at the interface of the microparticle with its
hydrophobic portion embedded in the PLGA matrix structure
and its hydrophilic portion available for hydration in the cell
culture media [7,24]. Furthermore, the anchored PVA can
provide functional OH groups, which have been reported as
being helpful in cell attachment [25]. Beside PVA, another
polymer—chitosan—was incorporated in the internal matrix
structure  for  better  cell  growth  of  cultured  cells  in  our
formulated microparticles. Here, chitosan can support cell
attachment  owing  to  its  chemical  structure  resembling
glycosaminoglycans,  which  is  abundant  in  extracellular
matrix components [26]. Similarly, sucrose was added (in the
internal phase of the primary emulsion sucrose) to increase
the surface tension of water [27]. Formation of larger water
droplets  upon  leaching  out  can  generate  more  porous
microparticles, which in turn provided more surface area to
promote cell adhesion, proliferation, and growth, as found in
our study.
Tumor  progression  ensues  within  a  3-D
microenvironment, and the metastatic potential of tumor cells
is believed to be regulated by interactions between the tumor
cells and their extracellular environment (i.e., ECM). These
interactions can be modified by the accumulation of genetic
changes and by the transient alterations in gene expression
induced by the local tumor microenvironment, which consists
of cellular and noncellular components. Noncellular aspects
of the tumor microenvironment, such as ECM, have been
shown  to  influence  tumor  progression  either  directly  by
destabilizing  tissue  integrity  and  promoting  tumor  cell
motility, invasion, and survival [28] or indirectly by inducing
tumor angiogenesis and enhancing tumor cell survival and
selection  [29,30].  3-D  tumor  models  using  different
substrates, such as Matrigel [31], laminin-rich extracellular
matrix [1], irradiated HeLa cells [32], or teflon membrane
[33,34], have been developed to study the various aspects of,
for  example,  tumor  biology,  phenotypic  alterations,  and
invasive and migratory behavior of cells. Y79 cells when
grown  on  porous  microparticles  tend  to  synthesize
extracellular matrix proteins, such as collagens (including
type I and III) and fibronectin, which together contribute to
the  mechanical  strength  of  the  tissue.  Collagenase  assay
analysis also showed significantly higher collagen synthesis
by Y79 cells grown on microparticles. It is known that in
tumor masses not all cancer cells are exposed to the same
concentration of drugs because of poor drug diffusion through
the extracellular matrix of the tumor [35]; this causes the
tumor to relapse or develop drug resistance [8]. Our study also
demonstrated significantly slow diffusion and heterogeneous
distribution of drugs and drugs encapsulated in nanoparticles
in the cells grown on PLGA–gelatin microparticles compared
to cells grown without. The important application of our study
TABLE 4. GENES UPREGULATED BY MORE THAN 0.5 FOLD BUT LESS THAN 1 FOLD IN Y79 CELLS GROWN WITH MICROPARTICLES COMPARED WITH CELLS GROWN WITHOUT
MICROPARTICLES. THESE GENES WERE CONSIDERED BASED ON THE BIOLOGIC AND STATISTICAL SIGNIFICANCE (P<0.05).
Gene ID Gene name Chromosome
location
Fold change significant p-
value <0.05
category
MCC Homo sapiens mutated in colorectal cancers (MCC), mRNA
[NM_002387]
chr5 0.5848 0.0041 oncogene
HMGA2 Homo sapiens high mobility group AT-hook 2 (HMGA2),
transcript variant 1, mRNA [NM_003483]
chr12 0.8396 0.0035 oncogene
MMP9 Homo sapiens matrix metallopeptidase 9 (gelatinase B,
92 kDa gelatinase, 92 kDa type IV collagenase) (MMP9),
mRNA [NM_004994]
chr20 0.6921 0.0041 Matrix
metallo
protease
DDX1 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
1 (DDX1), mRNA [NM_004939]
chr2 0.6986 0.0003 oncogene
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1373TABLE 5. GENES DOWN-REGULATED IN Y79 CELL GROWN WITH MICROPARTICLES (3-D) COMPARED TO THOSE WITHOUT MICROPARTICLES (2-D).
Gene name Protein name Fold change P value function
APAF-1 Homo sapiens apoptotic peptidase activating factor 1 (APAF1),
transcript variant 3, mRNA [NM_181861]
−1.9839 0.0012 Apaf-1, a cell-death effector that acts with
cytochrome c and caspase-9 to mediate
p53-dependent apoptosis
PIK3R3 Homo sapiens phosphoinositide-3-kinase, regulatory subunit 3
(p55, gamma) (PIK3R3), mRNA [NM_003629]
−1.644 0.0008 Pro-apoptosis.
SFRS1 Homo sapiens splicing factor, arginine/serine-rich 1 (splicing
factor 2, alternate splicing factor) (SFRS1), transcript variant 1,
mRNA [NM_006924]
−1.0263 0.0001 Pro-cell death
FKBP14 Homo sapiens FK506 binding protein 14, 22 kDa (FKBP14),
mRNA [NM_017946]
−0.9243 0.0099 Pro-apoptosis
PPP1R1B Homo sapiens protein phosphatase 1, regulatory (inhibitor)
subunit 1B (dopamine and cAMP regulated phosphoprotein,
DARPP-32) (PPP1R1B), transcript variant 1, mRNA
[NM_032192]
−1.5266 0.0007 Pro-apoptosis
ANXA5 Homo sapiens annexin A5 (ANXA5), mRNA [NM_001154] −3.7394 0.0002 Pro- apoptosis
TCF12 Homo sapiens transcription factor 12 (HTF4, helix–loop–helix
transcription factors 4) (TCF12), transcript variant 4, mRNA
[NM_207038]
−1.0896 0.0028 Pro apoptosis
PDCD2 Homo sapiens programmed cell death 2 (PDCD2), transcript
variant 1, mRNA [NM_002598]
−1.3256 0.0011 Pro apoptosis
ACTN4 Homo sapiens actinin, alpha 4 (ACTN4), mRNA
[NM_004924]
−1.3227 0 Pro apoptis
MAPK6 Homo sapiens mitogen-activated protein kinase 6 (MAPK6),
mRNA [NM_002748]
−1.1824 0.0236 Pro apoptosis
EIF5A2 Homo sapiens eukaryotic translation initiation factor 5A2
(EIF5A2), mRNA [NM_020390]
−1.4533 0.0001 Pro apoptosis
MAP3K13 Homo sapiens mitogen-activated protein kinase kinase kinase
13 (MAP3K13), mRNA [NM_004721]
−1.4791 0.0138 Pro apoptosis
HIST2H2BE Homo sapiens histone cluster 2, H2be (HIST2H2BE), mRNA −1.8046 0.001 Pro apoptosis
HIST1H1C Homo sapiens histone cluster 1, H1c (HIST1H1C), mRNA
[NM_005319]
−1.1425 0.0002 Pro apoptosis
PDCD6IP Homo sapiens programmed cell death 6 interacting protein
(PDCD6IP), mRNA [NM_013374]
−1.2727 0.0073 Pro apoptosis
CFL1 Homo sapiens cofilin 1 (non-muscle) (CFL1), mRNA
[NM_005507]
−1.1578 0.0068 Pro apoptosis
EIF2AK3 Homo sapiens eukaryotic translation initiation factor 2-alpha
kinase 3 (EIF2AK3), mRNA [NM_004836]
−1.502 0.0013 Proapoptosis
BUB3 Homo sapiens mRNA for BUB3 budding uninhibited by
benzimidazoles 3 isoform a variant, clone: hg01710.
[AK226060]
−1.7701 0.003 Pro apoptosis
ARHGAP21 Homo sapiens Rho GTPase activating protein 21
(ARHGAP21), mRNA [NM_020824]
−1.4986 0.0001 Anti metastasis
KRT17 Homo sapiens keratin 17 (KRT17), mRNA [NM_000422] −1.5924 0.0057 Anti metastasis
CD46 Homo sapiens CD46 molecule, complement regulatory protein
(CD46), transcript variant a, mRNA [NM_002389]
−1.3955 0.0004 Anti metastasis
SERPINH1 Homo sapiens serpin peptidase inhibitor, clade H (heat shock
protein 47), member 1, (collagen binding protein 1)
(SERPINH1), mRNA [NM_001235]
−1.1452 0 Anti-metastasis
BRMS1L Homo sapiens breast cancer metastasis-suppressor 1-like
(BRMS1L), mRNA [NM_032352]
−1.0558 0 Anti-metastasis
PANK3 Homo sapiens pantothenate kinase 3 (PANK3), mRNA
[NM_024594]
−0.9712 0.0019 Anti-metastasis
LGALS7 Homo sapiens lectin, galactoside-binding, soluble, 7 (galectin
7) (LGALS7), mRNA [NM_002307]
−1.0622 0.0002 Anti-metastasis
STK4 Homo sapiens serine/threonine kinase 4, mRNA (cDNA clone
IMAGE:3950315), complete cds. [BC005231]
−0.9328 0.0002 Tumor supression
PARP9 Homo sapiens poly (ADP-ribose) polymerase family, member
9 (PARP9), mRNA [NM_031458]
−1.4829 0.038 Tumor supression
CDKN1A Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1)
(CDKN1A), transcript variant
−2.0045 0.0027 Tumor supression
CDKN1C −4.2038 0.0002 Tumor supression
CDKN2C Homo sapiens cyclin-dependent kinase inhibitor 2C (p18,
inhibits CDK4) (CDKN2C), transcript variant 1, mRNA
[NM_001262]
−2.9462 0 Tumor supression
CDKN2A Homo sapiens cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4) (CDKN2A), transcript variant
3, mRNA [NM_058197]
−2.2861 0.0002 Tumor supression
KREMEN1 Homo sapiens kringle containing transmembrane protein 1
(KREMEN1), transcript variant 1, mRNA [NM_153379]
−1.3621 0.0034 Tumor supression
SASH1 Homo sapiens SAM and SH3 domain containing 1 (SASH1),
mRNA [NM_015278]
−4.8233 0 Tumor supression
RRM2 Homo sapiens ribonucleotide reductase M2 polypeptide
(RRM2), mRNA [NM_001034]
−1.309 0.0032 angiogenesis
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1374will be to predict the efficacy of drugs in vivo. Our study also
reports significant genomic variations in the cells when grown
with  porous  microparticles.  Enhanced  expression  of  the
collagen  family  members  laminin  and  fibronectin  were
observed in our study, which strongly supports our initial
findings.  In  response  to  collagen  synthesis,  we  observed
increased expression of matrix metalloproteinases (MMPs),
such as MMP-13 [36] and MMP-9 [37,38], the latter facilitates
the tumor cells to invade the extracellular matrix. Several
candidate genes, such as MYCN,ERBB3,JUN, and IGFBP5,
were also significantly upregulated, which keeps the tumor in
a proliferative state [11-15].
Changes in the upregulation of genes were coupled with
downregulation  of  a  few  genes  that  function  as  tumor
suppressor/apoptotic  inducers.  Homo  sapiens  APAF-1,
transcript variant 3, mRNA (Apaf-1) is a central component
of the intrinsic pathway of apoptosis and is important for
cellular  responses  to  DNA  damage  [39].  When  DNA  is
damaged  by  chemotherapeutic  agents,  oncogenic  stimuli,
ultraviolet and ionizing radiation, and hypoxia, cytochrome
c is released from the mitochondria, binds to Apaf-1 in the
cytosol,  and  in  association  with  dATP/ATP  facilitates  a
conformational change of Apaf-1 to expose its CARD domain
[40].  It  has  been  shown  that  inactivation  of  Apaf-1
substantially reduces the number of cells required to form
tumors in nude mice transplanted with Myc/Ras-transformed
fibroblasts, implying that Apaf-1 actually acts as a tumor
suppressor  [41].  Homo  sapiens  cyclin-dependent  kinase
inhibitor 2A (CDKN2A; melanoma, p16, inhibits CDK4), a
major CDK inhibitor, is the product of a tumor-suppressor
gene that has been found inactivated in different cancer types.
CDK  inhibitor  p21  (CDKN1A)  is  induced  by  both  p53-
dependent  and  p53-independent  mechanisms  following
stress, and induction of p21 may cause cell-cycle arrest; as a
proliferation inhibitor, p21 is poised to play an important role
in  preventing  tumor  development  [42].  This  notion  is
supported by data indicating that p21 null mice are more prone
to  spontaneous  and  induced  tumorigenesis  and  that  p21
TABLE 6. MICRORNAS DEREGULATED IN Y79 CELLS GROWN WITH MICROPARTICLES (3-D COMPARED TO CELLS WITHOUT
MICROPARTICLES (2-D).
miRNA Fold change Function p-value
miR-15a −1.0695 TS 0.0294
miR-16–1 −1.5218 TS 0.0429
miR-143 −1.5218 TS 0.0429
miR-145 −0.9849 TS 0.0168
hsa-let-7a −1.5014 TS 0.0231
hsa-let-7a* −1.0175 TS 0.0010
hsa-let-7b −1.4151 TS 0.0134
hsa-let-7c −1.2288 TS 0.0346
hsa-let-7c* −1.2534 TS 0.0429
hsa-let-7d −1.3859 TS 0.0132
hsa-let-7e −1.0035 TS 0.0480
hsa-let-7e* −1.2534 TS 0.0429
hsa-let-7f −1.4460 TS 0.0229
hsa-let-7f-1* −0.9678 TS 0.0054
hsa-let-7f-2* −1.2534 TS 0.0429
hsa-let-7g −1.0258 TS 0.0152
hsa-let-7g* −1.2534 TS 0.0429
hsa-let-7i* −1.2534 TS 0.0429
hsa-miR-125b −1.2534 TS 0.0429
hsa-miR-221 −1.5218 TS 0.0429
hsa-miR-19b 1.0548 OG 0.0386
hsa-miR-106a 1.0828 OG 0.0011
hsa-miR-18a 1.0100 OG 0.0053
hsa-miR-34a −1.4787 TS 0.0159
hsa-miR-34b −1.5218 TS 0.0429
hsa-miR-34c-5p 1.0000 OG 0.0483
hsa-miR-483–5p 1.1500 OG 0.0317
          TS: tumor suppressor, OG: oncogene.
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1375synergizes with other tumor suppressors to protect against
tumor progression in mice. Homo sapiens programmed cell
death  2  (PDCD2),  transcript  variant  1,  mRNA  promotes
apoptosis  in  several  human  lymphomas.  Repression  of
PDCD2  expression  by  BCL6,  which  in  turn  leads  to
downregulation of apoptosis, is one mechanism involved in
BCL6-associated lymphomatous transformation [43].
MicroRNAs  are  short  (20–23  nucleotides  in  length)
noncoding RNAs that mediate coordinated cellular programs
by  posttranscriptional  mRNA  silencing  and  protein
translation inhibition [44]. A growing number of miRNAs
have  been  implicated  in  promoting  or  suppressing
tumorigenesis in a variety of tissues [45,46], suggesting that
they may play a role as a novel class of oncogenes or tumor
suppressor genes. Our study revealed alterations in miRNA
expression when a Y79 cell line is grown with microparticles.
We  observed  enhanced  expression  of  oncogenic
microRNAs,  such  as  miR-18a,  miR-19b  [47],  miR-106a
[22],  and  miR-198  [20],  which  subsequently  promote
proliferation,  inhibit  apoptosis,  and  promote  tumor
angiogenesis.  There  was  also  decreased  expression  in
miRNAs, such as let-7 family [48], miR 15a and miR16–1
[49], and miR 34a [50] which act as tumor suppressors in
various  carcinomas,  including  retinoblastoma.  Let-7
downregulates oncogenes, such as Ras, Myc, and HMGA2,
and inhibits proliferation and tumorigenesis when ectopically
expressed [51].
In this study, we fabricated porous microparticles with a
composite interface containing PLGA and chitosan, which
Figure 10. This figure shows the real
time  quantitative  PCR  validation  of
selected genes from microarray results.
A: Graph shows real time quantitative
PCR  analysis  showing  upregulated
genes  (dark  bars)  in  Y79  cells  co-
cultured with microparticles (3-D) when
compared  with  Y79  cells  cultured
without microparticles (2-D). The fold
change  of  respective  genes  in
microarray  was  also  displayed  (gray
bars)  for  comparison.  The  genes  that
were upregulated in microarray analysis
were also found to be upregulated in
quantitative real time PCR analysis. B:
Graph shows real time quantitative PCR
analysis showing down-regulated genes
(dark bars) in Y79 cells co-cultured with
microparticles  (3-D)  when  compared
with  Y79  cells  cultured  without
microparticles (2-D). The fold change of
respective genes in microarray was also
displayed (gray bars) for comparison.
The genes that were down-regulated in
microarray analysis were also found to
be down-regulated in quantitative real
time  PCR  analysis.  The  error  bars
represent the data in triplicates.
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1376causes cancer cells to develop into a tumor-like structure in
vitro. The drug efficacy was significantly lower in cells grown
with  microparticles  than  in  cells  grown  without
microparticles, suggesting a role of cellular architecture on
drug  uptake,  distribution,  and  efficacy.  Our  tumor  model
could potentially be applicable in developing effective drugs
based  on  a  better  understanding  of  the  role  of  chemical,
biologic,  and  physical  parameters  in  the  process  of  drug
diffusion  through  the  tumor  mass,  drug  retention,  and
therapeutic outcome. A correlation between the drug effects
seen in the tumor model to the in vivo efficacy would further
establish the usefulness of our model in drug discovery. In
conclusion, we developed a novel, retinoblastoma, in vitro, 3-
D model that could be used for evaluating chemotherapeutic
drugs in the future.
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